Zdravstveni delavci (psihiater, psiholog, medicinska sestra ali socialni delavec) bodo v sodelovanju z bolnikom in njegovimi svojci postavili kratkoročne in dolgoročne cilje.
Nekaj primerov terapevtskih ciljev lahko preberete tu:1, 2, 9
obvladovanje oz. zmanjševanje simptomov in njihovega negativnega vpliva na življenje z namenom doseganja želene stopnje funkcioniranja,
preprečevanje ponovitve bolezni,
preprečevanje hospitalizacij,
preprečevanje ali lajšanje možnih neželenih učinkov zdravljenja,
vrnitev k vsakodnevnim dejavnostim (npr. delo, študij, samostojno življenje, druženje).
Literatura
APA Clinical Guidelines. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2004.
Falkai P et al. World J Biol Psychiatry 2005; 6: 132–191.
Kendler KS et al. Arch Gen Psychiatry 1996; 53: 1022–1031.
World Health Organization. The World Health Report: 2001: Mental health: new understanding, new hope.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM-IV-TR). Arlington: American Psychiatric Publishing Inc. 2000.
Lieberman JA et al. J Clin Psychiatry 1996; 57 (suppl 9): 5–9.
Breier A et al. Am J Psychiatry 1994; 151: 20–26.
Robinson DG et al. Am J Psychiatry 1999; 156: 544–549.
National Institute for Clinical Excellence. National Clinical Practice Guidelines Number 82.
Howard R et al. Am J Psychiatry 2000; 157: 172–178.
Angermeyer MC et al. Schizophr Bull 1990; 16: 293–307.
Murray RM and Fearon P. J Psychiatr Res 1999; 33: 497–499.
Lang UE et al. Cell Physiol Biochem 2007; 20: 687–702.
Harrigan SM et al. Psychol Med 2003; 33: 97 –110.
Bottlender R et al. Schizophr Res 2003; 62: 37–44.
Emsley R et al. Curr Opin Psychiatry 2008; 21: 173–177.
Awad AG et al. Pharmacoeconomics 2008; 26: 149–162.
Keith SJ et al. Psychiatr Serv 2004; 55: 997–1005.
Lieberman JA et al. Pharmacol Rev 2008; 60: 358–403.
Tandon R et al. Psychoneuroendocrinology 2003; 28 (suppl 1): 9–26.
Wyatt RJ. Schizophr Bull 1991; 17: 325–351.
Robinson DG et al. Arch Gen Psychiatry 1999; 56: 241–247.
Weiden PJ et al. Psychiatr Serv 2004; 55: 886–891.
Koen L et al. Psychosomatics 2007; 48: 128–134.
Novick D et al. Psychiatry Res 2010; 176: 109–113.
Kozma CM et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Research and Opinion. 2011.27; 1603–1611.